Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 12/2008

01.12.2008 | Article

Invasive group B streptococcus (GBS) disease in Norway 1996–2006

verfasst von: H. Bergseng, M. Rygg, L. Bevanger, K. Bergh

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to survey the occurrence of invasive group B streptococcus (GBS) disease in Norway and detect possible trends in characteristics of invasive GBS strains from1996 to 2006. Data from national monitoring systems for infectious diseases in Norway were analysed. Of 638,452 live births in the period, 434 cases of invasive GBS disease in infants were reported. In adults and children older than 1  year of age, 969 cases were reported. The incidence of invasive GBS disease increased significantly in the elderly, while the incidence of neonatal early-onset disease was stable with 0.46 cases per 1,000 live births. The incidence of late-onset disease increased in 2005 and 2006. The lethality of GBS in infants increased from an average of 6.5% in 1996–2005 to 20% in 2006. Serotypes III and V were predominant in 839 invasive GBS strains characterized—type III in infants and type V in the elderly. The distribution of serotypes did not change throughout the period. The distribution of detected surface proteins was stable from 1996 to 2005, but the detection rates in types III and V were low. Molecular methods for GBS typing introduced in 2006 made characterization of nearly all strains possible and appear more applicable to epidemiological studies of GBS than conventional methods. Resistance to erythromycin and clindamycin increased significantly in 2006. The increased incidence in the elderly, the increased lethality in infants in 2006, and the increased resistance to erythromycin and clindamycin the same year might indicate changing characteristics of invasive GBS strains.
Literatur
2.
Zurück zum Zitat Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cieslak PR, Schuchat A (2000) Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 342:15–20. DOI 10.1056/NEJM200001063420103 PubMedCrossRef Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cieslak PR, Schuchat A (2000) Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 342:15–20. DOI 10.​1056/​NEJM200001063420​103 PubMedCrossRef
3.
Zurück zum Zitat Lyytikainen O, Nuorti JP, Halmesmaki E, Carlson P, Uotila J, Vuento R, Ranta T, Sarkkinen H, Ammala M, Kostiala A, Jarvenpaa AL (2003) Invasive group B streptococcal infections in Finland: a population-based study. Emerg Infect Dis 9:469–473PubMed Lyytikainen O, Nuorti JP, Halmesmaki E, Carlson P, Uotila J, Vuento R, Ranta T, Sarkkinen H, Ammala M, Kostiala A, Jarvenpaa AL (2003) Invasive group B streptococcal infections in Finland: a population-based study. Emerg Infect Dis 9:469–473PubMed
4.
Zurück zum Zitat Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A (2002) Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 51:1–22PubMed Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A (2002) Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 51:1–22PubMed
5.
Zurück zum Zitat Boyer KM, Gotoff SP (1986) Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 314:1665–1669PubMed Boyer KM, Gotoff SP (1986) Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 314:1665–1669PubMed
7.
Zurück zum Zitat Tyrrell GJ, Senzilet LD, Spika JS, Kertesz DA, Alagaratnam M, Lovgren M, Talbot JA (2000) Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study–1996. Sentinel Health Unit Surveillance System Site Coordinators. J Infect Dis 182:168–173. DOI 10.1086/315699 PubMedCrossRef Tyrrell GJ, Senzilet LD, Spika JS, Kertesz DA, Alagaratnam M, Lovgren M, Talbot JA (2000) Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study–1996. Sentinel Health Unit Surveillance System Site Coordinators. J Infect Dis 182:168–173. DOI 10.​1086/​315699 PubMedCrossRef
10.
Zurück zum Zitat Lancefield RC, Freimer EH (1966) Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) 64:191–203 Lancefield RC, Freimer EH (1966) Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) 64:191–203
12.
Zurück zum Zitat Baker CJ, Kasper DL (1976) Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 294:753–756PubMed Baker CJ, Kasper DL (1976) Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 294:753–756PubMed
14.
Zurück zum Zitat Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS (2003) Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 188:66–73. DOI 10.1086/375536 PubMedCrossRef Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS (2003) Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 188:66–73. DOI 10.​1086/​375536 PubMedCrossRef
15.
Zurück zum Zitat Fluegge K, Supper S, Siedler A, Berner R (2005) Serotype distribution of invasive group B streptococcal isolates in infants: results from a nationwide active laboratory surveillance study over 2 years in Germany. Clin Infect Dis 40:760–763. DOI 10.1086/427942 PubMedCrossRef Fluegge K, Supper S, Siedler A, Berner R (2005) Serotype distribution of invasive group B streptococcal isolates in infants: results from a nationwide active laboratory surveillance study over 2 years in Germany. Clin Infect Dis 40:760–763. DOI 10.​1086/​427942 PubMedCrossRef
16.
Zurück zum Zitat Harrison LH, Elliott JA, Dwyer DM, Libonati JP, Ferrieri P, Billmann L, Schuchat A (1998) Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis 177:998–1002PubMed Harrison LH, Elliott JA, Dwyer DM, Libonati JP, Ferrieri P, Billmann L, Schuchat A (1998) Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis 177:998–1002PubMed
18.
Zurück zum Zitat Bevanger L, Kvam AI, Maeland JA (1995) A Streptococcus agalactiae R protein analysed by polyclonal and monoclonal antibodies. APMIS 103:731–736PubMedCrossRef Bevanger L, Kvam AI, Maeland JA (1995) A Streptococcus agalactiae R protein analysed by polyclonal and monoclonal antibodies. APMIS 103:731–736PubMedCrossRef
19.
Zurück zum Zitat Smith BL, Flores A, Dechaine J, Krepela J, Bergdall A, Ferrieri P (2004) Gene encoding the group B streptococcal protein R4, its presence in clinical reference laboratory isolates & R4 protein pepsin sensitivity. Indian J Med Res 119(suppl):213–220PubMed Smith BL, Flores A, Dechaine J, Krepela J, Bergdall A, Ferrieri P (2004) Gene encoding the group B streptococcal protein R4, its presence in clinical reference laboratory isolates & R4 protein pepsin sensitivity. Indian J Med Res 119(suppl):213–220PubMed
20.
Zurück zum Zitat Stalhammar-Carlemalm M, Stenberg L, Lindahl G (1993) Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med 177:1593–1603. DOI 10.1084/jem.177.6.1593 PubMedCrossRef Stalhammar-Carlemalm M, Stenberg L, Lindahl G (1993) Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med 177:1593–1603. DOI 10.​1084/​jem.​177.​6.​1593 PubMedCrossRef
21.
Zurück zum Zitat Larsson C, Lindroth M, Nordin P, Stalhammar-Carlemalm M, Lindahl G, Krantz I (2006) Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed 91:F403–F408. DOI 10.1136/adc.2005.090472 PubMedCrossRef Larsson C, Lindroth M, Nordin P, Stalhammar-Carlemalm M, Lindahl G, Krantz I (2006) Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed 91:F403–F408. DOI 10.​1136/​adc.​2005.​090472 PubMedCrossRef
22.
Zurück zum Zitat Bevanger L, Maeland JA (1977) Type classification of group B streptococci by the fluorescent antibody test. Acta Pathol Microbiol Scand [B] 85B:357–362 Bevanger L, Maeland JA (1977) Type classification of group B streptococci by the fluorescent antibody test. Acta Pathol Microbiol Scand [B] 85B:357–362
24.
Zurück zum Zitat Borchardt SM, Foxman B, Chaffin DO, Rubens CE, Tallman PA, Manning SD, Baker CJ, Marrs CF (2004) Comparison of DNA dot blot hybridization and lancefield capillary precipitin methods for group B streptococcal capsular typing. J Clin Microbiol 42:146–150. DOI 10.1128/JCM.42.1.146-150.2004 PubMedCrossRef Borchardt SM, Foxman B, Chaffin DO, Rubens CE, Tallman PA, Manning SD, Baker CJ, Marrs CF (2004) Comparison of DNA dot blot hybridization and lancefield capillary precipitin methods for group B streptococcal capsular typing. J Clin Microbiol 42:146–150. DOI 10.​1128/​JCM.​42.​1.​146-150.​2004 PubMedCrossRef
25.
Zurück zum Zitat Moyo SR, Maeland JA, Bevanger L (1999) Comparison of three different methods in monoclonal antibody-based detection of Streptococcus agalactiae protein serotype markers. APMIS 107:263–269PubMed Moyo SR, Maeland JA, Bevanger L (1999) Comparison of three different methods in monoclonal antibody-based detection of Streptococcus agalactiae protein serotype markers. APMIS 107:263–269PubMed
26.
Zurück zum Zitat Zeng X, Kong F, Morgan J, Gilbert GL (2006) Evaluation of a multiplex PCR-based reverse line blot-hybridization assay for identification of serotype and surface protein antigens of Streptococcus agalactiae. J Clin Microbiol 44:3822–3825. DOI 10.1128/JCM.01232-06 PubMedCrossRef Zeng X, Kong F, Morgan J, Gilbert GL (2006) Evaluation of a multiplex PCR-based reverse line blot-hybridization assay for identification of serotype and surface protein antigens of Streptococcus agalactiae. J Clin Microbiol 44:3822–3825. DOI 10.​1128/​JCM.​01232-06 PubMedCrossRef
30.
Zurück zum Zitat Fluegge K, Siedler A, Heinrich B, Schulte-Moenting J, Moennig MJ, Bartels DB, Dammann O, von KR, Berner R (2006) Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 117:e1139–e1145. DOI 10.1542/peds.2005-2481 PubMedCrossRef Fluegge K, Siedler A, Heinrich B, Schulte-Moenting J, Moennig MJ, Bartels DB, Dammann O, von KR, Berner R (2006) Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 117:e1139–e1145. DOI 10.​1542/​peds.​2005-2481 PubMedCrossRef
32.
Zurück zum Zitat Persson E, Berg S, Trollfors B, Larsson P, Ek E, Backhaus E, Claesson BE, Jonsson L, Radberg G, Ripa T, Johansson S (2004) Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998–2001. Clin Microbiol Infect 10:791–796. DOI 10.1111/j.1469-0691.2004.00931.x PubMedCrossRef Persson E, Berg S, Trollfors B, Larsson P, Ek E, Backhaus E, Claesson BE, Jonsson L, Radberg G, Ripa T, Johansson S (2004) Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998–2001. Clin Microbiol Infect 10:791–796. DOI 10.​1111/​j.​1469-0691.​2004.​00931.​x PubMedCrossRef
36.
Zurück zum Zitat Poyart C, Tazi A, Reglier-Poupet H, Billoet A, Tavares N, Raymond J, Trieu-Cuot P (2007) Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J Clin Microbiol 45:1985–1988. DOI 10.1128/JCM.00159-07 PubMedCrossRef Poyart C, Tazi A, Reglier-Poupet H, Billoet A, Tavares N, Raymond J, Trieu-Cuot P (2007) Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J Clin Microbiol 45:1985–1988. DOI 10.​1128/​JCM.​00159-07 PubMedCrossRef
Metadaten
Titel
Invasive group B streptococcus (GBS) disease in Norway 1996–2006
verfasst von
H. Bergseng
M. Rygg
L. Bevanger
K. Bergh
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 12/2008
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0565-8

Weitere Artikel der Ausgabe 12/2008

European Journal of Clinical Microbiology & Infectious Diseases 12/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.